We’re excited to share that Kiniksa’s Pharmaceuticals Phase 2/3 clinical trial of KPL-387, a potential treatment for recurrent pericarditis, is now actively recruiting participants.
If you or someone you know is living with recurrent pericarditis, we encourage you to consider participating in this important study. Clinical trials play a critical role in advancing care and finding better solutions for patients. Recurrent pericarditis is a painful and often debilitating condition, and new treatment options are urgently needed.
This trial, sponsored by Kiniksa Pharmaceuticals, is designed to evaluate the safety and effectiveness of KPL-387, a novel therapy that may help reduce inflammation and prevent future flare-ups. You can learn more about the trial and see if you or a someone you know might qualify by visiting:
